ResultsIQ

ResultsIQ › Latest results › IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited Q1 FY27 results deck summary

NSE: IOLCP · BSE: 524164

Results deck of 12 Aug 2026, summarised by AI from the filing.

Revenue ₹756.3 cr (+37.1% YoY), EBITDA ₹111.7 cr (+60.7% YoY), PAT ₹64.5 cr (+89.9% YoY).

Key takeaways

  1. Q1 FY27 results Revenue ₹756.3 cr (+37.1% YoY), EBITDA ₹111.7 cr (+60.7% YoY), PAT ₹64.5 cr (+89.9% YoY).
  2. Risk Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Original filing on BSE

IOL Chemicals and Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹756 cr (+37% year on year), EBITDA ₹103 cr (+64% year on year), PAT ₹64.4 cr (+89% year on year), EBITDA margin 13.7% (+227 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹619 cr (+17% year on year), EBITDA ₹92.5 cr (+47% year on year), PAT ₹53.2 cr (+71% year on year), EBITDA margin 14.9% (+300 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 300 bps year on year. Profit rose ₹22.2 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: +18.2% in 30 days (Nifty 500: +2.8%).
  • Q3 FY26: Revenue ₹580 cr (+11% year on year), EBITDA ₹57.3 cr (+22% year on year), PAT ₹20.6 cr (+38% year on year), EBITDA margin 9.9% (+88 bps). Score 72 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 88 bps year on year. Profit fell 3% from last quarter. Share price after the results: −15.0% in 30 days (Nifty 500: −9.9%).
  • Q2 FY26: Revenue ₹568 cr (+8% year on year), EBITDA ₹56.0 cr (+33% year on year), PAT ₹30.0 cr (+58% year on year), EBITDA margin 9.9% (+187 bps). Score 77 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 187 bps year on year. Profit fell 12% from last quarter. Share price after the results: −5.4% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹552 cr (+10% year on year), EBITDA ₹63.0 cr (+21% year on year), PAT ₹34.0 cr (+13% year on year), EBITDA margin 11.4% (+105 bps). Score 71 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 105 bps year on year. Share price after the results: +1.9% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹528 cr (+5% year on year), EBITDA ₹63.0 cr (+31% year on year), PAT ₹31.0 cr (+11% year on year), EBITDA margin 11.9% (+241 bps). Score 71 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 241 bps year on year. Share price after the results: +10.6% in 28 days (Nifty 500: +0.2%).
  • Q3 FY25: Revenue ₹523 cr (+1% year on year), EBITDA ₹47.0 cr (+7% year on year), PAT ₹21.0 cr (−9% year on year), EBITDA margin 9.0% (+53 bps). Score 55 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 53 bps year on year.
  • Q2 FY25: Revenue ₹526 cr (−3% year on year), EBITDA ₹42.0 cr (−34% year on year), PAT ₹19.0 cr (−50% year on year), EBITDA margin 8.0% (−376 bps). Score 10 of 100, Below trend. EBITDA margin fell 376 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 37% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

IOL Chemicals and Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.